Live Breaking News & Updates on Sixty Degree

Stay updated with breaking news from Sixty degree. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Cutting-Edge Trading Innovation: Sixty Degree Capital Unveils AI-Powered MT5 Trading Bot

Cutting-Edge Trading Innovation: Sixty Degree Capital Unveils AI-Powered MT5 Trading Bot
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Antonio Peterson , Oscar Donald Tyler , Company Name , Newsfile Corp , Degree Capital , Sixty Degree Capital , Meta Trader , Chief Trading Officer , Sixty Degree , Person Name ,

Daily Crunch: Meta decimates its staff as the social media giant lays off 11,000

Hello, friends, and welcome to Daily Crunch, bringing you the most important startup, tech and venture capital news in a single package. ....

United States , Akamai Technologies , Big Tech Inc , Techcrunch Top , Shasta Ventures , Sixty Degree , Image Credits , Greg Soh ,

Arcellx Raises $115M in Series C Financing


Arcellx, a Gaithersburg, Md.-based clinical-stage biopharmaceutical company advancing a pipeline of adaptive and controllable cell therapies, raised $115m in Series C financing.
The round was co-led by Samsara BioCapital and CAM Capital, joined by new investors Adage, Asymmetry, CaaS Capital, Cambrian Bio, Sixty Degree, Soleus Capital, Surveyor Capital (a Citadel company), Suvretta, and Terra Magnum Capital Partners, and existing investors NEA, Novo Holdings, SR One, Takeda Ventures, LG Tech, and Clough Capital.
The company intends to use the funds to develop CART-ddBCMA, a BCMA-specific CAR-modified T-cell therapy currently in Phase 1 and anticipated to begin a pivotal trial in 2022, and initiate clinical trials evaluating ACLX-001 and ACLX-002, cell therapies derived from its controllable ARC-SparX platform, in multiple myeloma (MM) and acute myelogenous leukemia (AML), respectively. ....

Novo Holdings , Samsara Biocapital , Caas Capital , Cambrian Bio , Sixty Degree , Soleus Capital , Surveyor Capital , Terra Magnum Capital Partners , Takeda Ventures , Rami Elghandour , Chief Executive Officer , நோவோ ஹோல்டிங்ஸ் , சாஸ் மூலதனம் , அறுபது பட்டம் , நிலமளப்போர் மூலதனம் , டெர்ரா மகத்தானது மூலதனம் கூட்டாளர்கள் , டாகேடா முயற்சிகள் , தலைமை நிர்வாகி அதிகாரி ,